These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 32687345)
1. Structure-Based Virtual Screening to Discover Potential Lead Molecules for the SARS-CoV-2 Main Protease. Gahlawat A; Kumar N; Kumar R; Sandhu H; Singh IP; Singh S; Sjöstedt A; Garg P J Chem Inf Model; 2020 Dec; 60(12):5781-5793. PubMed ID: 32687345 [TBL] [Abstract][Full Text] [Related]
2. Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19. Rai H; Barik A; Singh YP; Suresh A; Singh L; Singh G; Nayak UY; Dubey VK; Modi G Mol Divers; 2021 Aug; 25(3):1905-1927. PubMed ID: 33582935 [TBL] [Abstract][Full Text] [Related]
3. Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CL Liu WS; Li HG; Ding CH; Zhang HX; Wang RR; Li JQ Aging (Albany NY); 2021 Mar; 13(5):6258-6272. PubMed ID: 33678621 [TBL] [Abstract][Full Text] [Related]
4. Novel cyclohexanone compound as a potential ligand against SARS-CoV-2 main-protease. Basu S; Veeraraghavan B; Ramaiah S; Anbarasu A Microb Pathog; 2020 Dec; 149():104546. PubMed ID: 33011363 [TBL] [Abstract][Full Text] [Related]
5. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV. Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605 [TBL] [Abstract][Full Text] [Related]
6. Binding mechanism of inhibitors to SARS-CoV-2 main protease deciphered by multiple replica molecular dynamics simulations. Liang S; Liu X; Zhang S; Li M; Zhang Q; Chen J Phys Chem Chem Phys; 2022 Jan; 24(3):1743-1759. PubMed ID: 34985081 [TBL] [Abstract][Full Text] [Related]
7. An Updated Review on SARS-CoV-2 Main Proteinase (M Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134 [TBL] [Abstract][Full Text] [Related]
8. Conserved interactions required for inhibition of the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Shitrit A; Zaidman D; Kalid O; Bloch I; Doron D; Yarnizky T; Buch I; Segev I; Ben-Zeev E; Segev E; Kobiler O Sci Rep; 2020 Nov; 10(1):20808. PubMed ID: 33257760 [TBL] [Abstract][Full Text] [Related]
9. Docking-based virtual screening studies aiming at the covalent inhibition of SARS-CoV-2 M Soulère L; Barbier T; Queneau Y Comput Biol Chem; 2021 Jun; 92():107463. PubMed ID: 33677227 [TBL] [Abstract][Full Text] [Related]
10. 2-Pyridone natural products as inhibitors of SARS-CoV-2 main protease. Forrestall KL; Burley DE; Cash MK; Pottie IR; Darvesh S Chem Biol Interact; 2021 Feb; 335():109348. PubMed ID: 33278462 [TBL] [Abstract][Full Text] [Related]
11. Disulfiram inhibits coronaviral main protease by conjugating to its substrate entry site. Kuan Y; Chu HF; Hsu PH; Hsu KC; Lin TH; Huang CH; Chen WY Int J Biol Macromol; 2024 Sep; 276(Pt 2):133955. PubMed ID: 39025177 [TBL] [Abstract][Full Text] [Related]
14. Exploiting Hydrophobic Amino Acid Scanning to Develop Cyclic Peptide Inhibitors of the SARS-CoV-2 Main Protease with Antiviral Activity. Harrison K; Carlos PW; Ullrich S; Aggarwal A; Johansen-Leete J; Sasi VM; Barter I; Maxwell JWC; Bedding MJ; Larance M; Turville S; Norman A; Jackson CJ; Nitsche C; Payne RJ Chemistry; 2024 Aug; 30(44):e202401606. PubMed ID: 38801240 [TBL] [Abstract][Full Text] [Related]
15. Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease. Hajbabaie R; Harper MT; Rahman T Molecules; 2021 Feb; 26(4):. PubMed ID: 33672721 [TBL] [Abstract][Full Text] [Related]
16. Structure-guided design of a perampanel-derived pharmacophore targeting the SARS-CoV-2 main protease. Deshmukh MG; Ippolito JA; Zhang CH; Stone EA; Reilly RA; Miller SJ; Jorgensen WL; Anderson KS Structure; 2021 Aug; 29(8):823-833.e5. PubMed ID: 34161756 [TBL] [Abstract][Full Text] [Related]
17. Hispidin and Lepidine E: Two Natural Compounds and Folic Acid as Potential Inhibitors of 2019-novel Coronavirus Main Protease (2019- nCoVM Serseg T; Benarous K; Yousfi M Curr Comput Aided Drug Des; 2021; 17(3):469-479. PubMed ID: 32321407 [TBL] [Abstract][Full Text] [Related]
18. Targeted design of drug binding sites in the main protease of SARS-CoV-2 reveals potential signatures of adaptation. Padhi AK; Tripathi T Biochem Biophys Res Commun; 2021 May; 555():147-153. PubMed ID: 33813274 [TBL] [Abstract][Full Text] [Related]
20. Comparative Antiviral Efficacy of Viral Protease Inhibitors against the Novel SARS-CoV-2 In Vitro. Zhang L; Liu J; Cao R; Xu M; Wu Y; Shang W; Wang X; Zhang H; Jiang X; Sun Y; Hu H; Li Y; Zou G; Zhang M; Zhao L; Li W; Guo X; Zhuang X; Yang XL; Shi ZL; Deng F; Hu Z; Xiao G; Wang M; Zhong W Virol Sin; 2020 Dec; 35(6):776-784. PubMed ID: 32910347 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]